Jeffrey A. Bourret, PharmD

Authored Items
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry
Gary Branning, MBA, Dimitrios A. Pappas, MD, Robert A. Gerber, PharmD, MA, MBA, Heather J. Litman, PhD, David Gruben, PhD, Jamie Geier, PhD, Winnie D. Hua, MS, Connie Chen, PharmD, Youfu Li, MD, MPH, Joel M. Kremer, MD, John S. Andrews, MD, Jeffrey A. Bourret, PharmD
May 2018 Vol 11, No 3 in Clinical, Original Research
The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives
Steven R. Feldman, MD, PhD, Gary M. Owens, MD, Bernard Goffe, MD, Gary Rice, MBA, Matthew Mitchell, PharmD, MBA, FAMCP, Mandeep Kaur, MD, MS, Debbie Robertson, MS, RDN, LDN, Debra Sierka, PharmD, Jeffrey A. Bourret, PharmD, Tamara S. Evans, PharmD, MPH, BCPS, Alice Gottlieb, MD, PhD
December 2016 Vol 9, No 9 in Clinical
Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials
Abdullah K. Alahmari, BPharm, PhD candidate, Jeffrey A. Bourret, PharmD, Ziyad S. Almalki, BPharm, PhD candidate, Ahmed K. Alahmari,, Medical Student, Jeff J. Guo, BPharm, PhD
June 2016 Vol 9, No 4 in Clinical
Diagnosis and Treatment of Patients with Thyroid Cancer
Melinda G Huang, Jeffrey A. Bourret, PharmD, Aashish Khullar, MD, Eun Joo Lee, Quang T. Nguyen, DO, FACE, FTOS, Young In Park, DO, Raymond A. Plodkowski, MD
February 2015 Vol 8, No 1
New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidence
Charles Jia-Haur Hu, DO, Jeffrey A. Bourret, PharmD, Chihyi Lin, DO, Brien Rex Miller, DO, Hanh Nguyen, DO, Quang T. Nguyen, DO, FACE, FTOS
November 2014 Vol 7, No 8 in Clinical
Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population
Saurabh Ray, PhD, Machaon M. K. Bonafede, PhD, MPH, Nimish A. Mohile, MD, Jeffrey A. Bourret, PharmD
May 2014 Vol 7, No 3 in Clinical
Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: Current and Future Pharmacologic Approaches to Improving Outcomes
Mary Ann Banerji, MD, FACP, Jeffrey D. Dunn, PharmD, MBA, Jeffrey A. Bourret, PharmD
September 2013, Vol 6, No 7 in Business
Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care
Annette Powers, PharmD, MBA, Claudio Faria, PharmD, MPH, Eunice Chang, PhD, Dasha Cherepanov, PhD, Jeffrey A. Bourret, PharmD
November/December 2012 Vol 5, No 7 in Business
Quality Improvement Initiatives: The Missed Opportunity for Health Plans
Sara Fernandez-Lopez, PhD, Jeffrey A. Bourret, PharmD, Barbara Lennert, RN, BSN, MAOM
November/December 2009, Vol 2, No 7 in Regulatory
Last modified: April 11, 2019
SUBSCRIBE
Copyright © Amplity Medical Communications. All rights reserved.